Drilldown: Medicines

None (2) · Olopatadine (1)

Ajovy (1) · Emgality (1) · Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal) (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (1) · [[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (1) · [[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]] (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)

0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1) · Once daily (Pataday 0.7%); BID (other ophthalmic) (1)

intranasal (1) · Subcutaneous (2) · Topical ophthalmic (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

~27 days (1) · ~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1) · ~31 days (1)

Not formally established (1) · Not formally established (high SC) (1) · Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1)

Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (2)

OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) · Rx (2)